|
|
The IMF Honors 2022 Kyle and Durie Achievement Awardees: Dr. Avet-Loiseau and Dr. Paiva
The International Myeloma Foundation (IMF) is proud to announce the recipients of this year’s Robert A. Kyle Lifetime Achievement Award and Brian G.M. Durie Outstanding Achievement Award. The awards ceremony was held in-person on Wednesday, June 8th, at the 13th Annual International Myeloma Working Group (IMWG) Summit in Vienna, Austria. These two major IMF achievement awards are presented each year to outstanding and deserving individuals who have made significant contributions in the field of myeloma research. This year’s Robert A. Kyle Lifetime Achievement Awardee is Hervé Avet-Loiseau, MD, PhD, Head of the Laboratory for Genomics in Myeloma at the University Hospital Center of Toulouse, France for 10 years; Head of the Hematology Laboratory at the University Hospital of Nantes, France since 2008; and current Chairman of the Intergroupe Francophone du Myélome (IFM). This year’s Brian G.M. Durie Outstanding Achievement Awardee is Bruno Paiva, PharmD, PhD, co-director of the Flow Cytometry Platform and co-director of the Monoclonal Gammopathies Research Laboratory at the CIMA Universidad De Navarra in Pamplona, Spain. Dr. Paiva is also a key member of the i2TEAMM, which seeks FDA and EMA approvals for MRD testing as a surrogate response endpoint in myeloma clinical trials. To know more about this year’s IMF Achievement awardees, read the IMF’s press release.
|
|
|
|
|
|
|
Register Now: IMWG Conference Series 2022 – Making Sense of Treatment
At the upcoming IMWG Conference Series, “Making Sense of Treatment” on Thursday, June 16, 2 p.m. ET (US and Canada), leading myeloma experts will discuss the latest drug therapy news from the June 2022 American Society of Clinical Oncology (ASCO) Annual Conference, IMF IMWG Summit, and the European Hematology Association (EHA) Annual Conference. Moderated by IMF Chairman of the Board Dr. Brian G.M. Durie, panelists will include Drs. Vincent Rajkumar (Mayo Clinic—Rochester, MN) and María V. Mateos (University of Salamanca—Salamanca, Spain).
|
|
|
|
|
|
|
IMF Virtual Regional Community Workshop (RCW) - New England
The IMF Regional Community Workshop – New England will be held on Saturday, June 18 at 7:00 a.m. PT/ 8:00 a.m. MDT/ 9:00 a.m. CT/ 10:00 a.m. ET. IMF Senior Director of Regional Community Workshops Kelly Cox will kick off the workshop. Guest speakers include Rafat Abonour, MD, (Indiana University—Indianapolis, IN), Raymond Comenzo, MD (Tufts Medical Center—Boston, MA), and IMF Nurse Leadership Board (NLB) Member Kimberly Noonan, DNP, ANP-BC, AOCN (Dana-Farber Cancer Institute—Boston, MA). The workshop will include an introduction to myeloma, upfront treatments at diagnosis, maintenance therapy, relapse information, and an update on clinical trials. IMF NLB Member Kimberly Noonan will talk about managing side effects and symptoms of myeloma and its treatments. After each presentation with the experts, attendees will have ample time to ask questions.
|
|
|
|
|
|
|
Living Well with Myeloma Webinar on June 23
The Living Well with Myeloma Webinar, on Thursday, June 23, at 7 p.m. ET, will focus on “A Promising Future for Treating Multiple Myeloma with Bispecific Antibodies.” IMF Vice President of Support Groups Robin Tuohy will moderate presentations with the following speakers: Donna Catamero, ANP-BC, OCN, CCRC (The Mount Sinai Health Center—New York, NY, IMF Nurse Leadership Board), and Tom Martin, MD (University of California San Francisco—San Francisco, CA). To ensure patients and care partners better understand the promising future in bispecific therapies, please tune in to this Live Webinar to hear from Tom Martin, MD and Donna Catamero, ANP-BC, OCN, CCRC, as they cover key questions, concerns, and highlights.
|
|
|
|
|
|
|
M-Power: Changing the Course of Myeloma in the African American Community
The IMF M-Power Initiative is focused on changing the course of myeloma in the African American community. Myeloma is two times as common in people of African descent as it is in all other races and ethnicities. Empower yourself by joining our 2nd virtual M-Power Charlotte webinar on June 25, 10 a.m.–12:30 p.m. ET. Event panelists include Dr. Peter Voorhees (Levine Cancer Institute – Charlotte); Tiffany W. Crank, MPH (Levine Cancer Institute – Charlotte); IMF Nurse Leadership Board member Amy E. Pierre, RN, MSN, ANP-BC; local myeloma patient and advocate, Pastor Robert Pugh; IMF Patient, President & CEO Yelak Biru; and IMF Chief Medical Officer Dr. Joseph Mikhael. Panelists will be participating in real time and answering your questions.
|
|
|
|
|
|
|
Download Understanding VELCADE® (bortezomib) injection–2022 Edition
Velcade plays an important role in the treatment of myeloma. Velcade is used in induction therapy for the newly diagnosed, as part of a conditioning regimen for stem cell transplant, as consolidation therapy, maintenance therapy, and for the treatment of patients whose myeloma has relapsed or has become refractory to prior therapies. Get your FREE copy of the IMF’s Understanding VELCADE® (bortezomib) injection in printed form or as a downloadable PDF with hyperlinks to informative resources.
|
|
|
|
|
|
Instagram @IMFmyeloma